Variability in intestinal drug metabolizing enzymes and transporters in Crohn's disease and potential impact on oral drug absorption

Documenti analoghi

• Changes in Protein Expression of Renal Drug Transporters and Drug‐Metabolizing Enzymes in Autosomal Dominant Polycystic Kidney Disease Patients
  di: Annika C. Tillmann, et al.
  Pubblicazione: (2025)
• The quantitative impact of metabolism‐inhibiting drugs on the occurrence of adverse drug reactions—A backward selection approach
  di: Judith Berres, et al.
  Pubblicazione: (2026)
• Therapeutic drug monitoring, liquid biopsies or pharmacogenomics for prediction of human drug metabolism and response
  di: Magnus Ingelman‐Sundberg, et al.
  Pubblicazione: (2024)
• Identification of drug repurposing candidates for the treatment of polycystic kidney disease
  di: Alina Meyer, et al.
  Pubblicazione: (2026)
• A drug–drug interaction study and physiologically based pharmacokinetic modelling to assess the effect of an oral 5‐lipoxygenase activating protein inhibitor on the pharmacokinetics of oral midazolam
  di: Jane Knöchel, et al.
  Pubblicazione: (2024)